IXICO plc Collaboration with TRACK-FA NeuroimagingConsortium (9326Z)
24 Septiembre 2020 - 1:00AM
UK Regulatory
TIDMIXI
RNS Number : 9326Z
IXICO plc
24 September 2020
IXICO plc
("IXICO" or the "Company")
Collaboration with TRACK-FA Neuroimaging Consortium
IXICO joins the TRACK-FA Neuroimaging Consortium to develop
novel imaging markers in Friedreich's Ataxia
IXICO plc (AIM: IXI), the data analytics company delivering
insights in neuroscience, announces that it has entered into a 5
year collaboration with the Friedreich's Ataxia Research Alliance
(FARA), a non-profit organization dedicated to the pursuit of
scientific research leading to treatments and a cure for
Friedreich's Ataxia (FA). IXICO will become a member of the
TRACK-FA Neuroimaging Consortium, working with clinicians and
researchers to explore novel imaging markers in Friedreich's
Ataxia.
FA is a rare inherited, debilitating, life-limiting,
degenerative neuro-muscular disorder, and although rare, it is the
most common form of hereditary ataxia in the United States,
affecting about 1 in every 50,000 people. FA causes progressive
nervous system damage and movement problems and usually begins in
childhood and leads to impaired muscle coordination (ataxia) that
worsens over time, with the rate of progression varying from person
to person. Generally, within 10 to 20 years after the appearance of
the first symptoms the person is confined to a wheelchair.
The TRACK-FA Neuroimaging Consortium is a representative group
of stakeholders with interest in the design, conduct, support and
participation in neuroimaging studies in FA, facilitating the
exchange of data and other information with the goal of furthering
the understanding of FA, identifying sensitive neuroimaging
biomarkers and advancing the development of treatments for FA.
IXICO will support the implementation of novel analysis algorithms,
with the aim of providing a trial ready imaging solution for FA
clinical trials.
IXICO will be an industry member and stakeholder in the
consortium, working alongside academic partners with expertise in
neuroimaging and conducting clinical research in FA. These partners
include Monash University (Australia), University of Minnesota
(USA), Aachen University (Germany), University of Campinas
(Brazil), University of Florida (USA), and Children's Hospital of
Philadelphia (USA).
This contract does not have significant impact on management's
expectations of performance for the year but will contribute to the
Company's already strong year end order book.
Dr Robin Wolz, Senior Vice President for Science and Innovation
at IXICO, commented, "This new consortium will help to accelerate
the quest for new treatments for Friedreich's Ataxia by bringing
together some of the leading researchers in the field from both
academia and industry with the specific goal of developing new
tools to better understand and characterise this debilitating
disease. IXICO will bring its expertise in neuroimaging and AI to
support the development and validation of new biomarkers which in
turn will help to identify the most promising treatments and bring
these to patients sooner."
For further information please contact:
IXICO plc +44 (0)20 3763 7498
Giulio Cerroni, Chief Executive
Officer
Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser
and sole broker) +44 (0)20 7397 8900
Giles Balleny / Max Gould (Corporate
Finance)
Michael F Johnson / Russell Kerr
(Sales)
Walbrook PR Ltd + 44 (0)20 7933 8780
Paul McManus / Lianne Cawthorne IXICO@walbrookpr.com
/
Alice Woodings
About IXICO
IXICO is dedicated to delivering insights in neuroscience. Our
purpose is to advance medicine and human health by turning data
into clinically meaningful information, providing valuable new
insights in neuroscience and our goal is to be a leading proponent
of artificial intelligence in medical image analysis. We will
achieve this by developing and deploying breakthrough data
analytics, at scale, through our remote access technology platform,
to improve the return on investment in drug development and reduce
risk and uncertainty in clinical trials for our pharmaceutical
clients.
More information is available on www.IXICO.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAXNDAEXEEFA
(END) Dow Jones Newswires
September 24, 2020 02:00 ET (06:00 GMT)
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Ixico (LSE:IXI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024